Low-dose zoledronic acid appeared safe among older patients with hip fracture and advanced chronic kidney disease.

Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

December 16, 2010 — Treatment with zoledronic acid (Zometa) appears to have benefits beyond bone health in patients with multiple myeloma. Researchers in the United Kingdom report that overall ...

Zoledronic acid, a bone strengthening drug, given together with chemotherapy might decrease the spread of cancer in women with locally advanced breast cancer by reducing the likelihood of tumour cells ...

Zoledronic acid administration during the initial hospitalization for osteoporotic hip fracture significantly reduces all-cause mortality and subsequent vertebral fractures among older patients.

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

Bone mineral density increases were seen in prostate cancer patients on ADT who took the drug for two years. STOCKHOLM—Treatment with zoledronic acid for two years in men who are undergoing androgen ...

Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance.

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or ...

September 26, 2011 (Stockholm, Sweden) — Further analysis of a subgroup from the large AZURE trial shows that when zoledronic acid (Zometa) was added to chemotherapy in postmenopausal women with ...